Login / Signup

Antibody and T-cell responses 6 months after COVID-19 mRNA-1273 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant.

Jan Stephan F SandersA Lianne MesschendorpRory D de VriesCarla C BaanDebbie van BaarleRob van BinnendijkDimitri A DiavatopoulosDaryl GeersKatharina S SchmitzCorine H Geurts van KesselGerco den HartogMarcia Ml KhoMarion Pg KoopmansRenate G van der MolenEster Bm RemmerswaalNynke RotsRon T GansevoortFrederike J BemelmanLuuk B HilbrandsMarlies Ej Reindersnull null
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Although seropositivity rates at 6 months were comparable to that at 28 days after vaccination, significantly decreased antibody levels and T-cell responses were observed. The combination of low antibody levels, reduced T-cell responses, and absent neutralization of the newly-emerging variants indicates the need for additional boosts or alternative vaccination strategies in KTR.
Keyphrases
  • coronavirus disease
  • sars cov
  • chronic kidney disease
  • gene expression
  • copy number
  • end stage renal disease
  • respiratory syndrome coronavirus